期刊文献+

乳腺癌内分泌治疗新药fulvestrant临床研究进展 被引量:8

Research progress of fulvestrant:A novel drug used in breast cancer endocrine therapy
下载PDF
导出
摘要 Fulvestrant是一种新型雌激素受体(ER)阻滞剂,其降低乳腺癌细胞中ER水平的作用明显优于三苯氧胺(TAM)。初步研究表明,在晚期乳腺癌治疗中,fulvestrant与现有的内分泌治疗药物间无交叉耐药,其疗效略优于TAM,至少与阿那曲唑等效且副作用较小,具有较广泛的应用前景。 Fulvestrant is a novel oestrogen receptor(ER)antagonist that has higher efficacy than TAM in downregulating ER.Recent studies suggest that fulvestrant has no cross-resistance with TAM or anromatase inhibitors(Ais).In the treatment of postmenopausal women with advanced breast cancer, fulvestrant has higher effect than TAM and as same as Ais, with good tolerability.So fulvestrant has extensive prospect in breast cancer endocrine therapy.
出处 《癌症进展》 2005年第4期342-344,共3页 Oncology Progress
关键词 乳腺癌 内分泌治疗 FULVESTRANT breast cancer endocrine therapy fulvestrant
  • 相关文献

参考文献13

  • 1[1]Defriend DJ, Howell A, Nicholson RI et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res, 1994, 54 (2) :408 被引量:1
  • 2[2]Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha- [9- (4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl] estra-l,3,5, (10)-triene-3, 17-beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res, 2001, 61 (18) :6739 被引量:1
  • 3[3]Wakeling AE, Dukes M, Bavler J, et al. A potent specific pure antiestrogen with clinical potential. Cancer Res, 1991, 51(15):3867 被引量:1
  • 4[4]Wakeling AE. Similarities and distinctions in the mode of action of different classes of antiestrogens. Endocr Relat Cancer, 2000, 7(1) :17 被引量:1
  • 5[5]Osborne CK, Coronado H EB, Hildenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst,1995, 87 (10) :746 被引量:1
  • 6[6]Osborne CK, Jarman M, Mcague R, et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.Cancer Chemother Pharmacol, 1994, 34 (2) :89 被引量:1
  • 7[7]Howell A, Defriend D, Robertson J, et al. Response to a specific antiestrogen (ICI 182, 780) in tamoxifen-resistant breast cancer. Lancet, 1995, 345 (8941) :29 被引量:1
  • 8[8]Howell A, Defriend D, Robertson J, et al. Pharmacokinetics,Pharmacological, and antitumor effects of the specific anti-oestrogen ICI 182, 780 in women with advanced breast cancer. Br J Cancer, 1996, 74 (2) :300 被引量:1
  • 9[9]Mauriac L, Pippen J. E, Quaresma J, et al. Fulvestrant(FaslodexTM ) verses anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. European Journal of Cancer, 2003, 39 (9):1228 被引量:1
  • 10[10]Robertson J, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trial. Cancer, 2003, 98 (2) :229 被引量:1

同被引文献91

引证文献8

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部